<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000789982">
  <TermName>Nerlynx</TermName>
  <TermPronunciation>(NAYR-links)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug used alone or with capecitabine to treat adults with certain types of HER2-positive breast cancer that have already been treated. It is also being studied in the treatment of other types of cancer. Nerlynx blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called neratinib maleate.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000790333" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Nerlynx&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000790332" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Nerlynx&quot;" language="es" id="_4"/>
  <SpanishTermName>Nerlynx</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento que se usa solo o con capecitabina para el tratamiento de adultos con ciertos tipos de cáncer de mama positivo para HER2 que ya recibió tratamiento. Además, está en estudio para el tratamiento de otros tipos de cáncer. Nerlynx bloquea ciertas proteínas, lo que quizás ayude a evitar la multiplicación de células cancerosas y las destruya. Es un tipo de inhibidor de tirosina–cinasas. También se llama maleato de neratinib.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2017-07-20</DateFirstPublished>
  <DateLastModified>2021-10-22</DateLastModified>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000790070" url="/about-cancer/treatment/drugs/neratinibmaleate">Neratinib Maleate</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
